全文获取类型
收费全文 | 28431篇 |
免费 | 2560篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 301篇 |
儿科学 | 1101篇 |
妇产科学 | 590篇 |
基础医学 | 3618篇 |
口腔科学 | 451篇 |
临床医学 | 3554篇 |
内科学 | 4851篇 |
皮肤病学 | 503篇 |
神经病学 | 2806篇 |
特种医学 | 843篇 |
外国民族医学 | 1篇 |
外科学 | 3995篇 |
综合类 | 644篇 |
一般理论 | 23篇 |
预防医学 | 3439篇 |
眼科学 | 431篇 |
药学 | 2089篇 |
中国医学 | 45篇 |
肿瘤学 | 1761篇 |
出版年
2023年 | 239篇 |
2022年 | 339篇 |
2021年 | 791篇 |
2020年 | 438篇 |
2019年 | 756篇 |
2018年 | 884篇 |
2017年 | 619篇 |
2016年 | 608篇 |
2015年 | 684篇 |
2014年 | 943篇 |
2013年 | 1336篇 |
2012年 | 1896篇 |
2011年 | 1955篇 |
2010年 | 1088篇 |
2009年 | 963篇 |
2008年 | 1523篇 |
2007年 | 1533篇 |
2006年 | 1462篇 |
2005年 | 1436篇 |
2004年 | 1294篇 |
2003年 | 1230篇 |
2002年 | 1176篇 |
2001年 | 651篇 |
2000年 | 575篇 |
1999年 | 492篇 |
1998年 | 266篇 |
1997年 | 225篇 |
1996年 | 261篇 |
1995年 | 199篇 |
1994年 | 188篇 |
1993年 | 166篇 |
1992年 | 361篇 |
1991年 | 351篇 |
1990年 | 375篇 |
1989年 | 336篇 |
1988年 | 278篇 |
1987年 | 300篇 |
1986年 | 224篇 |
1985年 | 250篇 |
1984年 | 207篇 |
1983年 | 158篇 |
1982年 | 138篇 |
1981年 | 108篇 |
1980年 | 120篇 |
1979年 | 170篇 |
1978年 | 143篇 |
1977年 | 112篇 |
1976年 | 102篇 |
1974年 | 128篇 |
1973年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
83.
BACKGROUND: We assessed suicide and suicide attempt risk as well as symptom reduction among 3,282 depressed patients participating in duloxetine and escitalopram clinical trials assigned to either an antidepressant or placebo. METHODS: We reviewed the FDA Summary Basis of Approval reports for data regarding safety and efficacy for duloxetine and escitalopram. Furthermore, we compared suicide risk among antidepressant clinical trials in this study with our two previous analyses on seven antidepressant clinical trials. RESULTS: Suicide and suicide attempt risk varied considerably among the three analyses, showing up to ten fold differences. Interestingly, the variability exists across the three reports, rather than between treatments (antidepressants versus placebo). CONCLUSIONS: These findings suggest caution in generalizing suicide risk even from a relatively large number of participants and thus, firm conclusions can only be drawn if the number of participants is overwhelmingly large (approximately two million patients). We also noted similar magnitude of response to placebo and antidepressants among the three studies. 相似文献
84.
Edward D Moloney Jim J Egan Peter Kelly Alfred E Wood Leslie T Cooper 《The Journal of heart and lung transplantation》2005,24(8):1103-1110
Myocarditis is a major cause of end-stage heart failure and is responsible for up to 10% of cases of idiopathic dilated cardiomyopathy (IDC). Worldwide, approximately 45% of all heart transplants are performed for IDC and up to 8% for myocarditis. Early reports suggested that survival after transplantation for myocarditis was poor and patients had an increased risk of rejection. More recently, larger case series suggest that overall survival after transplantation for myocarditis is similar to survival after transplantation for other causes. However, certain disorders, including cardiac sarcoidosis and giant cell myocarditis (GCM), require heightened surveillance for post-transplantation disease recurrence. We present the case of a 42-year-old man with recurrence of GCM 8 years after transplantation and review the literature on the role of cardiac transplantation for patients with myocarditis. 相似文献
85.
Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. In the US, the selegiline transdermal system (STS; EMSAM) is the first antidepressant transdermal delivery system to receive Food and Drug Administration (FDA) approved labeling for the treatment of major depressive disorder (MDD). Currently, the use of orally administered MAO inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the “cheese reaction”) when combined with dietary tyramine. The selegiline transdermal system is the only MAOI available in the US for the treatment of MDD that does not require dietary restriction at the clinically effective dose of 6 mg/24 hours. Delivery of selegiline transdermally (EMSAM®) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic MAO-A activity (ie, reduced risk of tyramine-provoked events) while still providing sufficient levels of selegiline in the brain to produce an antidepressant effect. At dosages of 6–12 mg/24 hours, EMSAM has been shown to improve symptoms of depression, have good tolerability, and have high rates of medication adherence. However, at higher doses of EMSAM (ie, 9 mg/24 hours or more), dietary restriction of tyramine intake is recommended. The introduction of EMSAM overcomes many of the safety concerns affiliated with the conventional oral MAO inhibitors and EMSAM may be considered another strategy for the treatment of MDD, especially in patients who cannot tolerate oral antidepressants, are poorly adherent, who present with atypical depressive symptoms, or have failed other antidepressants. 相似文献
86.
Richard A. Perugini Steven H. Quarfordt Stephen Baker Donald R. Czerniach Demetrius E. M. Litwin John J. Kelly 《Journal of gastrointestinal surgery》2007,11(9):1083-1090
Introduction Obese individuals may have normal insulin–glucose homeostasis, insulin resistance, or diabetes mellitus. Whereas gastric bypass
cures insulin resistance and diabetes mellitus, its effects on normal physiology have not been described. We studied insulin
resistance and β-cell function for patients undergoing gastric bypass.
Methods One hundred thirty-eight patients undergoing gastric bypass had fasting insulin and glucose levels drawn on days 0, 12, 40,
180, and 365. Thirty-one (22%) patients with diabetes mellitus were excluded from this analysis. Homeostatic model of assessment
was used to estimate insulin resistance, insulin sensitivity, and β-cell function. Based on this model, patients were categorized
as high insulin resistance if their insulin resistance was >2.3.
Results Body mass index did not correlate with insulin resistance. Forty-seven (34%) patients were categorized as high insulin resistance.
Correction of insulin resistance for this group occurred by 12 days postoperatively. Sixty (43%) patients were categorized
as low insulin resistance. They demonstrated an increase of β-cell function by 12 days postoperatively, which returned to
baseline by 6 months. At 1 year postoperatively, the low insulin resistance group had significantly higher β-cell function
per degree of insulin sensitivity.
Conclusions Adipose mass alone cannot explain insulin resistance. Severely obese individuals can be categorized by degree of insulin resistance,
and the effect of gastric bypass depends upon this preoperative physiology. 相似文献
87.
Paolo R. Salvalaggio Katie Neighbors Susan Kelly Karan M. Emerick Kishore Iyer Riccardo A. Superina Peter F. Whitington Estella M. Alonso 《American journal of transplantation》2005,5(8):1868-1874
The Pediatric End-Stage Liver Disease (PELD) score was designed to reduce subjectivity in liver allocation and to advantage patients with a higher probability of waiting list mortality. The aims of this study were to determine the impact of PELD implementation for children with chronic liver disease and to assess whether PELD met its goal of standardization of liver allocation for children. This study used data reported to the United Network for Organ Sharing (UNOS) registry for children with chronic liver disease receiving primary cadaveric liver transplant between January 2000 and December 2001 (pre-PELD) and March 2002 and July 2003 (PELD). PELD reduced the percentage of children transplanted while in an intensive care unit and as status 1. A calculated PELD score was used for allocation in only 52% of recipients. Thirty percent were status 1 at transplant and PELD scores granted by exception were used for allocation in 18% of patients. There was regional variation in PELD score at allocation and use of exception scores with a significant relationship between PELD score and percentage of exception cases. Regional variation suggests that PELD has not resulted in standardization of listing practices in pediatric liver transplantation. 相似文献
88.
W N Kelly E C Krause W J Krowinski T R Small J F Drane 《American journal of hospital pharmacy》1990,47(10):2245-2250
Whether and how drug information centers respond to calls from the public that involve ethical issues was studied. A survey describing six ethical dilemmas typical of those presented by calls from the public was mailed to pharmacists in 154 drug information centers to see how the questions would be handled. Centers that had written policies governing responses to questions with ethical implications were asked to submit those policies. One hundred twenty-six centers (82%) responded to the survey; of these, 81 (64.3%) answered questions from the public. There were no significant differences in characteristics between centers that did and did not respond to public calls. The case analyses, completed only by pharmacists in centers that responded to public calls, covered such issues as invasion of privacy, social responsibility, personal liability, and interference with the patient-physician relationship. Respondents exercised a wide degree of discretion in determining if they would answer a question; for example, while only 4% would not answer a question concerning the efficacy of a weight-loss diet patch, 77% reported they would not respond to a caller asking for information on drugs that could interfere with the results of a polygraph test. Although respondents often cited institutional policy as the reason for failing to respond to a question, none submitted a copy of such a policy. The pharmacists' responses indicated a high degree of moral and social sensitivity; nonetheless, written policies should be developed to assist drug information center staff members in handling questions that have ethical implications. 相似文献
89.
Twenty patients received transduodenal sphincteroplasty and transampullary septectomy between 1987
and 1993. Seven patients had post-cholecystectomy pain which was much improved or abolished in 5 of 7
patients at a mean follow-up of 4 years and 5 months. Four of five patients with chronic pancreatitis were
improved at 3 years and 2 months. Three of five patients with recurrent acute pancreatitis were improved
at 4 years and 5 months. One of three patients with chronic abdominal pain of hepatobiliary origin was
improved at 3 years. Transduodenal sphincteroplasty and transampullary septectomy can relieve pain in
patients with post-cholecystectomy pain, recurrent acute pancreatitis, chronic pancreatitis, and chronic
abdominal pain of hepatobiliary origin, presumably by improving drainage of the obstructed ducts. 相似文献
90.
Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. 总被引:29,自引:0,他引:29 下载免费PDF全文
K J Kelly W W Williams Jr R B Colvin J V Bonventre 《Proceedings of the National Academy of Sciences of the United States of America》1994,91(2):812-816
The pathophysiology of ischemic acute renal failure is complex, and the role of leukocyte adhesion in this process is not well defined. A monoclonal antibody (mAb) against intracellular adhesion molecule 1 (anti-ICAM-1), administered at the time of bilateral renal ischemia in the rat, prevented both functional impairment and histologic changes of acute renal failure. Plasma creatinine measured (mg/dl) 24 hr after 30 min of ischemia was 0.61 +/- 0.05 in the anti-ICAM-1-treated animals compared with 2.4 +/- 0.14 (P < 0.0001) in the vehicle-treated ischemic group. Forty-eight hours after ischemia, creatinine values were 0.46 +/- 0.05 and 2.03 +/- 0.22 (P < 0.0001) in anti-ICAM-1 and vehicle-treated groups, respectively. A low dose of anti-ICAM-1 that was itself nonprotective, when given with partially protective doses of a mAb against lymphocyte function-associated antigen-1 (anti-LFA-1), acted synergistically to prevent renal failure. Anti-ICAM-1 mAb also protected the kidney when administered 0.5 or 2 hr but not 8 hr after restoration of blood flow and when the ischemic period was extended to 40 min. Ischemia-induced increases in tissue myeloperoxidase, a marker of neutrophil infiltration, were mitigated with anti-ICAM-1 treatment. Thus, anti-ICAM-1 mAb protected the kidney against ischemic renal failure, even when the antibody was administered after the ischemic period. These results suggest a critical role for leukocytes and adhesion molecules in the pathophysiology of ischemic injury and may have important therapeutic implications. 相似文献